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Background: Non–small-cell lung cancers (NSCLCs) containing 
EGFR mutations are exquisitely sensitive to epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitors (TKIs). This is the case 
of the most common EGFR mutations affecting exon 18 (G719X), 
19 (inframe deletions), and 21 (L858R and L861Q). However, the 
frequency of compound (i.e., double or complex) EGFR mutations—
where an EGFR TKI sensitizing or other mutation is identified 
together with a mutation of unknown clinical significance—and their 
pattern of response/resistance to EGFR TKIs are less well described.
Methods: We analyzed the EGFR mutation pattern of 79 cases of 
NSCLC harboring EGFR mutations and compiled the genotype-
response data for patients with NSCLCs with compound EGFR 
mutations treated with EGFR TKIs.
Results: Of the 79 EGFR-mutated tumors identified, 11 (14%) had 
compound mutations. Most involved the EGFR TKI–sensitizing 
G719X (n = 3, plus S768I or E709A), L858R (n = 4, plus L747V, 
R776H, T790M, or A871G), L861Q (n = 1, plus E709V), and delL747_
T751 (n = 1, plus R776H). Eight patients received an EGFR TKI: three 
cases with G719X plus another mutation had partial responses (PRs) 
to erlotinib; of three cases with L858R plus another mutation, two dis-
played PRs and one (with EGFR-L858R+A871G) progressive disease 
(PD) to erlotinib; one NSCLC with EGFR-L861Q+E709A and one 
with delL747_T751+R776S had PRs to EGFR TKIs.
Conclusion: Compound EGFR mutations comprised 14% of all 
mutations identified during routine sequencing of exons 18–21 of 
EGFR in our cohort. Most patients with an EGFR TKI–sensitizing 
mutation (G719X, exon 19 deletion, L858R, and L861Q) in addition 
to an atypical mutation responded to EGFR TKIs. Reporting of the 
genotype-response pattern of NSCLCs with EGFR compound and 
other rare mutations, and the addition of this information to search-
able databases, will be helpful to select the appropriate therapy for 
EGFR-mutated NSCLC.
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compound, Exon 19 deletion double, Exon 19 deletion complex.
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Lung cancer is ranked as the most common cause of cancer death in the United States and many developed countries. 
Non–small-cell lung cancers (NSCLCs) are the most preva-
lent form of this disease, and the understanding of its genetic 
diversity has led to the potential for molecularly targeted inter-
ventions. In particular, mutations in the EGFR gene and trans-
locations involving the ALK or the ROS1 genes play a pivotal 
role in carcinogenesis of some lung cancers. Alterations in these 
actionable kinases predict the clinical effectiveness of tyrosine 
kinase inhibitors (TKIs) that target these aberrant oncogenes.1
There are a multitude of somatic mutations in the EGFR 
that have been described in NSCLC samples, and most cluster 
within the tyrosine kinase domain of this receptor tyrosine 
kinase. The most frequent—and clinically significant—
mutations include inframe deletions involving amino acids 
LREA of exon 19 and the exon 21 L858R. Together, these 
classic mutations account for almost 85% of all EGFR 
mutations. Gefitinib and erlotinib, oral epidermal growth 
factor receptor (EGFR) TKIs, have been extensively studied 
in clinical trials that included NSCLCs with classic EGFR 
mutations, and both drugs lead to superior response rates (RRs) 
and progression-free survivals (PFSs) when compared with 
standard platinum-doublet cytotoxic chemotherapies.1,2 RRs 
to gefitinib/erlotinib exceed 60% to 70% in these trials, with 
median PFSs of more than 9 to 10 months and overall survival 
times beyond 20 months.1 Other EGFR mutations have also 
been associated with enhanced effects of EGFR TKIs. These 
include the less-prevalent exon 18 G719X mutations (~3% of 
reported EGFR mutations) and the exon 21 L861Q (~2% of all 
EGFR mutations). In aggregate, G719X and L861Q mutated 
NSCLCs have been described to have RRs that exceed 50% 
and PFSs of more than 5 months in gefitinib/erlotinib-treated 
patients.3 On the contrary, other classes of EGFR mutations 
can be associated with lack of response to gefitinib or erlotinib. 
This is the case of the most prevalent EGFR exon 20 inframe 
insertion mutations (~5% of EGFR mutations) following the 
regulatory C-helix of EGFR.4
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Other EGFR mutations and tumors with multiple EGFR 
mutations have not been completely characterized. This 
is the case of compound EGFR mutations where an EGFR 
TKI–sensitizing mutation (such as G719X, exon 19 deletions, 
L858R or L861Q) coexists with uncommon mutations involv-
ing other residues of the tyrosine kinase domain of EGFR. In 
this study, we report the frequency of and responses to EGFR 
TKIs of our center’s cohort of compound EGFR-mutated 
NSCLCs and provide a review of the literature on the pat-
tern of response to EGFR TKIs of these mutation types. The 
date presented here will enhance efforts, such as Vanderbilt 
University’s DNA-mutation Inventory to Refine and Enhance 
Cancer Treatment (DIRECT) database (http://www.mycan-
cergenome.org), to compile a searchable database for oncolo-
gists treating patients genotyped for EGFR mutations and 
other genetic alterations.5
PATIENTS AND METHODS
Patient Selection
Patients with a diagnosis of NSCLC and whose tumors 
were genotyped for EGFR mutations up to August 1, 2012, 
were identified through an ongoing Institutional Review 
Board–approved protocol at Beth Israel Deaconess Medical 
Center (BIDMC2009-P-000182).
Tumor Genotype
EGFR mutation analysis was performed using standard 
DNA sequencing techniques with direct sequencing of exons 
18 to 21 of EGFR. In brief, DNA was isolated from the sample, 
quantified and amplified by polymerase chain reaction (PCR) 
using primers to exons 18 to 21 of EGFR.6 PCR products were 
analyzed by bidirectional direct DNA sequencing. Tumor geno-
type was performed in baseline diagnostic specimens before 
patient exposure to EGFR TKIs.
Data Collection
We reviewed the BIDMC electronic medical records and 
radiographic studies to obtain clinical and pathologic infor-
mation such as EGFR mutation status and response to EGFR 
TKIs. Response was calculated using Response Evaluation 
Criteria In Solid Tumors version 1.1. Study data were col-
lected and managed using REDCap electronic data capture 
tools hosted at BIDMC.
Statistical Methods
The reporting of parameters involving clinical, patho-
logic, radiographic, response data, and tumor genotypes used 
descriptive methods.
RESULTS
Frequency of EGFR Mutations
Table 1 summarizes the frequency of EGFR mutations 
identified during routine clinical genotype of our patients’ 
tumor specimens. Most mutations were single mutations 
(67 of 79, 84.75%) with exon 19 deletions (34 of 79, 43%) and 
L858R (24 of 79, 30.5%) being the most prevalent mutation 
types. EGFR exon 20 insertion mutations (6.3%), plus single 
mutations involving G719X (1.25%) and L861Q (2.5%) were 
less frequent. Of the 79 unique tumors, 11 (14%) had com-
pound mutations (Table 1).
EGFR Compound Mutations
 Most (9 of 11, 81.8%) EGFR compound mutations 
involved the EGFR TKI–sensitizing G719X (n = 3), L858R 
(n = 4), L861Q (n =1), and delL747_T751 (n = 1) mutations 
(Table 1). The partner mutation identified during sequencing 
was either an exon 18 atypical mutation (E709X, n = 2), an 
exon 19 atypical mutation (L747V, n = 1), an exon 20 atypical 
mutation (S7681, n = 2; R776S, n = 2; T790M, n = 1), or an 
exon 21 atypical mutation (A871G, n = 1). Table 1 summa-
rizes how these combinations paired in each specific tumor.
TABLE 1.  Frequency of Different EGFR Mutations Detected 
in NSCLC Samples by Direct Sequencing of Exons 18–21 of 
EGFR
EGFR Mutation Type No. % of Total
Single mutations 67 84.75
 exon 18 mutations 2 2.5
  E709_T710delETinsD 1 1.25
  G719A 1 1.25
 exon 19 deletions 34 43
  delE746_A750 26 33
  delE746_S752insV 2 2.5
  delL747_A750insP 1 1.25
  delL747_T751 3 3.75
  delL747_S752 1 1.25
  delL747_A753insQ 1 1.25
 exon 20 insertions 5 6.30
  A763_Y764insFQEA 1 1.25
  D770delDinsGY 1 1.25
  P772_H773dupH 2 2.5
  P772_H773dupPH 1 1.25
 exon 21 mutations 26 33
  L858R 24 30.5
  L861Q 2 2.5
Compound mutations 11 14
 G719A+S768I 2 2.5
 G719S+E709A 1 1.25
 delL747_T751+R776S 1 1.25
 S768I+V769L 1 1.25
 H773L+V774M 1 1.25
 L858R+L747V 1 1.25
 L858R+R776H 1 1.25
 L858R+T790M 1 1.25
 L858R+A871G 1 1.25
 L861Q+E709V 1 1.25
Other mutation 1 1.25
 G724fs 1 1.25
Total 79 100
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Response to EGFR TKIs of  
EGFR-Mutated NSCLCs
Of the 11 patients with tumor genotype revealing a 
compound EGFR mutation, eight received an EGFR TKI dur-
ing their clinical course. Table 2 summarizes seven patients 
who only received erlotinib.
Of the three cases with G719X plus another mutation, 
all had PR to erlotinib (at concentrations of 100–150 mg/day). 
However, in none did the PFS exceed 8 months, and in none 
did the survival exceed 12 months.
Out of the three cases with L858R plus another muta-
tion, the patients whose tumors had L858R+L747V and 
L858R+R776H displayed PRs that are ongoing (Table 2). 
The patient (who had a poor performance status at diagno-
sis) whose tumor had L858R+A871G had rapid PD and died 
within 3 months of starting erlotinib 150 mg per day (Table 2).
One patient with an exon 19 deletion (delL747_
T751)+R776S mutated NSCLC, who had her initial clini-
cal course detailed previously,7 had a prolonged response to 
a low dose of erlotinib with a PFS of 20 months (Table 2). 
The final patient (a 68-year-old white, never-smoker, with 
Eastern Cooperative Oncology Group performance status of 
0 and stage IV adenocarcinoma) with an NSCLC harboring 
L861Q+E709A had a prolonged PR (decreased in 48% of tar-
get lesions) to an experimental irreversible EGFR TKI (as first-
line systemic therapy) that lasted for 25 months, followed by an 
additional 7 months of erlotinib at a dose of 150 mg per every 
other day until further progression at month 32 of EGFR TKIs.
DISCUSSION
EGFR mutations are considered the most robust predictive 
biomarker for the clinical and radiographic responses attained 
by EGFR TKIs in clinical practice. Single EGFR mutations or 
multiple mutations can be identified during sequencing of exon 
18 to 21 of EGFR. The clinical prevalence and significance of 
multiple mutations have not been completely ascertained. One 
of the largest cohorts of EGFR-mutated NSCLCs disclosed that 
approximately 7% of the tumors harbored compound mutations 
involving the EGFR TKI–sensitizing mutations G719X, exon 
19 deletions, L858R, and L861Q in combination with other 
EGFR mutations in Taiwanese patients.3 Others have reported 
frequencies lower than 4% for these mutations.8 The method 
of EGFR mutation detection (direct sequencing of exon 18–21 
[as used in this report], mutant-enriched PCR, peptide nucleic 
acid-locked nucleic acid (PNA-LNA) PCR, PCR clamp, allele-
specific reactions, high-resolution melting analysis, Applied 
Biosystems Prism SNaPshot Multiplex system, among others) 
and the potential introduction of artifacts generated in the PCR 
step may account for the unequal prevalence of compound 
mutations in prior series.5,9 The cohort reported here indicated 
a higher prevalence of EGFR compound mutations in 14% of 
our 79 cases. Therefore, it seems that the frequency of EGFR 
compound mutations is not insignificant.
The genotype-clinical/radiographic response pattern 
of EGFR compound mutations has not been completely 
defined and neither has there been a concerted effort to 
determine whether these compound mutations occur in cis 
or in trans within EGFR alleles. We will summarize the 
available literature below. NSCLCs with G719X mutations 
in addition to other mutations are commonly reported. As an 
example, in the aforementioned Taiwanese cohort, eight of the 
15 NSCLCs with G719X harbored compound G719X plus 
other mutations and the RR for G719X mutations (single + 
compound) was 53.3% with a PFS of 8.1 months.3 In our data 
set, three fourths (75%) G719X mutations were compound. 
The EGFR-G719A+S768I mutation, which we identified in 
two patients with PR to erlotinib, has been reported by others 
in two NSCLCs that had lack of responses to gefitinib,10,11 and 
EGFR-S768I alone has been reported in a gefitinib-responsive 
NSCLC.12 The in vitro characterization of G719S+S768I 
showed that this EGFR is as sensitive to gefitinib as G719S 
alone.13 An NSCLC with G719S+E709A, which we identified 
in one patient with PR to erlotinib, has been previously reported 
as having a PR to the irreversible EGFR TKI neratinib.14 The 
in vitro characterization of G719C+E709A demonstrated that 
the resulting EGFR protein is only slightly less sensitive to 
gefitinib than G719C alone,15 which may not be significant 
at clinical doses used for erlotinib (at 150 mg/day, the serum 
trough exceeds 1.5μM) or irreversible EGFR TKIs.16 Exon 19 
deletions are less frequently identified as compound mutations, 
outside the setting of acquired resistance to gefitinib/erlotinib 
where they are frequently found with EGFR-T790M that 
shifts the ensuing proteins into resistant patterns to clinically 
achievable doses of gefitinib and erlotinib.17 It seems other 
compound exon 19 mutations, such as the erlotinib responsive 
EGFR-delL747_T751+R776H reported by our group,7 retain 
their responsiveness to EGFR TKIs.
L858R mutations are frequently reported as a part of 
compound mutations, with approximately 10% of L858R 
mutated NSCLC in association with other mutations.3 We 
identified five of 29 (17.25%) of our EGFR-L858R as com-
pound mutations. How these compound mutations affect the 
response to gefitinib and erlotinib of L858R alone is not com-
pletely known. Our group has characterized in vitro EGFR-
L858R+L747S and shown that this compound mutation shifts 
the sensitivity curve to EGFR TKIs in a manner that would 
make it resistant to trough serum concentrations of a dose 
of gefitinib 250 mg/day (<0.5μM) but not to serum troughs 
(>0.5–1μM) of erlotinib at doses above 50 to 100 mg per day.18 
The same seems true for L858R+D761Y.19 We and others have 
also shown that EGFR-L858R+T790M is resistant to gefi-
tinib and erlotinib at their maximum tolerated doses.16,18 The 
in vitro characterization of L858R+E709A, L858R+E709G, 
and L858R+L838V showed that these EGFRs are as sensi-
tive to gefitinib as L858R alone.13 In this report, we show 
that NSCLCs with L858R+L747V and L858R+R776H had 
PRs to erlotinib. A prior NSCLC with L858R+R776H has 
also been described as having PR to gefitinib.11 The case of 
EGFR-L858R+A871G NSCLC reported here as having PD 
to erlotinib 150 mg per day may indicate that this compound 
mutation may confer resistance to EGFR TKIs; an assertion 
that will require in vitro modeling. EGFR-L858R+H870R in 
vitro is less sensitive to gefitinib than L858R alone.15
L861Q mutations can be part of compound mutations 
in more than half of EGFR-L861Q positive cases identi-
fied. We observed one third (33.3%) of cases of L861Q as 
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a compound mutation. Others have reported RRs as high as 
60% for single or compound mutant L861Q bearing tumors 
with PFSs of 6 months.3 We report a L861Q+E709A muta-
tion that had a prolonged PR to an experimental irrevers-
ible EGFR TKI followed by additional disease control with 
erlotinib.
In summary, compound EGFR mutations comprised 
14% of all mutations identified during routine sequencing of 
exons 18 to 21 of EGFR in our cohort. Most tumors with an 
EGFR sensitizing mutation (G719X, exon 19 deletions, L858R, 
and L861Q) in addition to an atypical mutation responded to 
EGFR TKIs. Reporting of the genotype-response pattern of 
NSCLCs with EGFR compound and other rare mutations will 
help define the complete spectrum of how EGFR genotype 
affects the response to EGFR TKIs of NSCLCs.
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(pack-yr) Histology
EGFRTKI 
(Line of 
Therapy)
Dose (for 
>50%  
Course)
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Never(0) Adenocarcinoma Erlotinib  
(first line)
100 mg/day PR –33.3 7 7 10
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EGFR, epidermal growth factor receptor; PS, Eastern Cooperative Oncology Group performance status; TKI, tyrosine kinase inhibitor; NSCLC, non–small-cell lung cancer; 
NOS, not otherwise specified; RECIST, Response Evaluation in Solid Tumors version 1.1; PD, progressive disease; PFS, progression-free survival; OS, overall survival.
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